CollPlant Biotechnologies (CLGN) Gross Margin (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly Gross Margin came in at 332.88% in Q1 2026, down 42373.0% YoY from N/an in Q1 2025, and down 51.31% on a QoQ basis from 220.0% in Q4 2025.
CollPlant Biotechnologies (CLGN) Gross Margin (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of Gross Margin data on file, last reported at 332.88% in Q1 2026.
- Quarterly Gross Margin fell 42373.0% year-over-year to 332.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1799631.62% (down 179968033.0% YoY) and the FY2025 annual result came in at 64.78%, up 28032.0% from the prior year.
- Gross Margin slipped to 332.88% in Q1 2026, from 220.0% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 93.96% in Q2 2023 to a low of 3910614.53% in Q2 2025.
- A 5-year average of 244926.06% and a median of 128.73% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin soared 142842923 bps — and 2025, when it plunged 391049926 bps.
- Tracing CLGN's Gross Margin over 5 years: stood at 6.9% in 2022, then slumped by 2199 bps to 158.53% in 2023, then soared by 58 bps to 65.85% in 2024, then tumbled by 234 bps to 220.0% in 2025, then slumped by 51 bps to 332.88% in 2026.
- The last three Gross Margin figures came in at 332.88% (Q1 2026), 220.0% (Q4 2025), and 249.35% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | -332.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -332.88% |
| Dec 31, 2025 | -220.00% |
| Sep 30, 2025 | -249.35% |
| Jun 30, 2025 | -3,910,614.53% |
| Mar 30, 2025 | 90.85% |
| Dec 31, 2024 | -65.85% |
| Sep 30, 2024 | -6,700.00% |
| Jun 30, 2024 | -115.26% |
| Mar 31, 2024 | -456.12% |
| Dec 31, 2023 | -158.53% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 93.96% |
| Mar 31, 2023 | 24.94% |
| Dec 31, 2022 | -6.90% |
| Sep 30, 2022 | -142.20% |
| Jun 30, 2022 | 34.85% |
| Dec 31, 2021 | -76.77% |
| Sep 30, 2021 | -1,428,571.43% |
| Jun 30, 2021 | 37.92% |
| Mar 31, 2021 | 93.89% |